The Claim
In adults with overweight or obesity, administration of weekly pemvidutide at a dosage of 2.4 mg for 48 weeks leads to resolution of obesity (defined as BMI <30 kg/m²) in 48% of participants.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with overweight or obesity, a weekly injection of pemvidutide at 2.4 mg for 48 weeks resulted in nearly half of the participants achieving a body mass index below 30 kg/m², which is the clinical threshold for no longer being classified as obese.
See the scientific wording
In adults with overweight or obesity, weekly pemvidutide at 2.4 mg for 48 weeks results in resolution of obesity (BMI <30 kg/m²) in 48% of participants, indicating a clinically meaningful shift in disease classification.
The drug activates two receptors in the brain and liver that make you feel full faster and burn more calories, so you eat less and lose weight until your body mass drops below the obesity threshold.
What the research says
1 studyIn a study with obese adults, nearly half of those who got the highest dose of a new weight-loss drug (pemvidutide) once a week for 48 weeks dropped below the medical cutoff for obesity. That means their weight was no longer classified as obese.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.